Literature DB >> 24357249

Role of preoperative basal calcitonin levels in the timing of prophylactic thyroidectomy in patients with germline RET mutations.

Jean-Christophe Lifante1, Claire Blanchard, Eric Mirallié, Albert David, Jean-Louis Peix.   

Abstract

BACKGROUND: The American Thyroid Association (ATA) published recommendations for the timing of prophylactic surgery for medullary thyroid carcinoma based on the specific mutation, patient age, family history, and serum calcitonin levels. The aim of this study was to assess the role of preoperative basal calcitonin (prebCt) levels in predicting the presence of medullary carcinoma of the thyroid in patients with RET mutations.
METHODS: We conducted a retrospective study in two endocrine surgery departments. Between 1986 and 2012, a total of 32 patients with RET mutations underwent prophylactic thyroidectomy. The patients were stratified into four ATA risk levels: A, B, C, and D.
RESULTS: All of the patients were biologically cured. Microcarcinoma was observed in the final pathology report for four of the 20 patients with normal prebCt (25 %) and for nine of the 12 patients with elevated prebCt (75 %). In the level A group, four patients with normal prebCt and one patient with elevated prebCt presented with microcarcinoma. In the level C group, one patient with normal prebCt and six of the seven patients with elevated prebCt (86 %) presented with microcarcinoma.
CONCLUSIONS: PrebCt can predict the presence of microcarcinoma according to surgical pathological analysis. Patients with microcarcinoma can be biochemically and clinically cured using prophylactic thyroidectomy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24357249     DOI: 10.1007/s00268-013-2413-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  18 in total

1.  Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level.

Authors:  Andreas Machens; Ulrich Schneyer; Hans-Jürgen Holzhausen; Henning Dralle
Journal:  J Clin Endocrinol Metab       Date:  2005-01-05       Impact factor: 5.958

2.  Very early prophylactic thyroid surgery for infants with a mutation of the RET proto-oncogene at codon 634: evaluation of the implementation of international guidelines for MEN type 2 in a single centre.

Authors:  Christian Piolat; Jean-François Dyon; Nathalie Sturm; Stéphane Pinson; Michel Bost; Pierre-Simon Jouk; Dominique Plantaz; Olivier Chabre
Journal:  Clin Endocrinol (Oxf)       Date:  2006-07       Impact factor: 3.478

3.  The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.

Authors:  F Carlomagno; G Salvatore; A M Cirafici; G De Vita; R M Melillo; V de Franciscis; M Billaud; A Fusco; M Santoro
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

4.  C-cell hyperplasia preceding medullary thyroid carcinoma.

Authors:  H J Wolfe; K E Melvin; S J Cervi-Skinner; A A Saadi; J F Juliar; C E Jackson; A H Tashjian
Journal:  N Engl J Med       Date:  1973-08-30       Impact factor: 91.245

Review 5.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

6.  Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.

Authors:  Michael A Skinner; Jeffrey A Moley; William G Dilley; Kouros Owzar; Mary K Debenedetti; Samuel A Wells
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

7.  When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations?

Authors:  Patricia Niccoli-Sire; Arnaud Murat; Vincent Rohmer; Hélène Gibelin; Gerard Chabrier; Bernard Conte-Devolx; Jacques Visset; Jean Ronceray; Daniel Jaeck; Jean François Henry; Charles Proye; Bruno Carnaille; Jean Louis Kraimps
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

8.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

9.  Provocative testing for occult medullary carcinoma of the thyroid: findings in seven children with multiple endocrine neoplasia type IIa.

Authors:  S M Graham; M Genel; R J Touloukian; K W Barwick; J M Gertner; C Torony
Journal:  J Pediatr Surg       Date:  1987-06       Impact factor: 2.545

10.  Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study.

Authors:  Jennifer M J Schreinemakers; Menno R Vriens; Gerlof D Valk; Jan-Willem B de Groot; John T Plukker; Klaas M A Bax; Jaap F Hamming; Rob B van der Luijt; Daniel C Aronson; Inne H M Borel Rinkes
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

View more
  1 in total

1.  Serum calcitonin reference values for calcium stimulation tests by electrochemiluminescence immunoassay in Japanese men with non-medullary thyroid carcinoma.

Authors:  Minoru Kihara; Akira Miyauchi; Takumi Kudo; Mitsuyoshi Hirokawa; Akihiro Miya
Journal:  Surg Today       Date:  2017-08-18       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.